Krista Y Christensen1, Michelle Raymond2, Jon Meiman3. 1. University of Wisconsin-Madison Department of Ophthalmology and Visual Sciences, 610 Walnut Street, Madison, WI, 53726, USA. 2. Wisconsin Department of Health Services, 1 West Wilson Street, Madison, WI, 53703, USA; University of Wisconsin-Madison Department of Population Health Sciences, 614 Walnut Street, Madison, WI, 53726, USA. Electronic address: Michelle.Raymond@wisconsin.gov. 3. Wisconsin Department of Health Services, 1 West Wilson Street, Madison, WI, 53703, USA.
Abstract
BACKGROUND: Perfluoroalkyl substances (PFAS) are a class of contaminants used in many industrial applications and consumer products. Certain PFAS are regulated or voluntarily limited due to concern about environmental persistence and adverse health effects. OBJECTIVES: In this analysis we examine PFAS levels and their association with metabolic syndrome and its components, using a representative sample of the U.S. METHODS: Data on PFAS levels and metabolic syndrome components were collected from the 2007-2008, 2009-2010, 2011-2012, and 2013-2014 cycles of the National Health and Nutrition Examination Survey. Twelve different PFAS were measured in serum samples from participants. Logistic regression models were used to identify associations between metabolic syndrome, its individual components, and serum PFAS concentrations. RESULTS: Over one-third (37%) of participants met the definition for metabolic syndrome, with increased waist circumference and elevated glucose being the most commonly reported components. Seven PFAS were detected in at least 30% of participants and were examined in subsequent analyses (PFDA, PFOA, PFOS, PFHxS, MPAH, PFNA, PFUnDA). The PFAS with the highest concentrations was PFOS (median 8.4 ng/mL), followed by PFOA, PFHxS and PFNA. After adjusting for potential confounders, PFNA was associated with increased risk of metabolic syndrome and well as several individual components, while the highest levels of PFHxS were associated with elevated triglycerides. Other PFAS were associated with decreased risk of at least one outcome. CONCLUSIONS: Associations between PFAS and metabolic syndrome are inconsistent within and across studies. PFNA was consistently associated with increased risk for components of the syndrome, a finding that warrants further investigation.
BACKGROUND:Perfluoroalkyl substances (PFAS) are a class of contaminants used in many industrial applications and consumer products. Certain PFAS are regulated or voluntarily limited due to concern about environmental persistence and adverse health effects. OBJECTIVES: In this analysis we examine PFAS levels and their association with metabolic syndrome and its components, using a representative sample of the U.S. METHODS: Data on PFAS levels and metabolic syndrome components were collected from the 2007-2008, 2009-2010, 2011-2012, and 2013-2014 cycles of the National Health and Nutrition Examination Survey. Twelve different PFAS were measured in serum samples from participants. Logistic regression models were used to identify associations between metabolic syndrome, its individual components, and serum PFAS concentrations. RESULTS: Over one-third (37%) of participants met the definition for metabolic syndrome, with increased waist circumference and elevated glucose being the most commonly reported components. Seven PFAS were detected in at least 30% of participants and were examined in subsequent analyses (PFDA, PFOA, PFOS, PFHxS, MPAH, PFNA, PFUnDA). The PFAS with the highest concentrations was PFOS (median 8.4 ng/mL), followed by PFOA, PFHxS and PFNA. After adjusting for potential confounders, PFNA was associated with increased risk of metabolic syndrome and well as several individual components, while the highest levels of PFHxS were associated with elevated triglycerides. Other PFAS were associated with decreased risk of at least one outcome. CONCLUSIONS: Associations between PFAS and metabolic syndrome are inconsistent within and across studies. PFNA was consistently associated with increased risk for components of the syndrome, a finding that warrants further investigation.
Authors: Jerrold J Heindel; Sarah Howard; Keren Agay-Shay; Juan P Arrebola; Karine Audouze; Patrick J Babin; Robert Barouki; Amita Bansal; Etienne Blanc; Matthew C Cave; Saurabh Chatterjee; Nicolas Chevalier; Mahua Choudhury; David Collier; Lisa Connolly; Xavier Coumoul; Gabriella Garruti; Michael Gilbertson; Lori A Hoepner; Alison C Holloway; George Howell; Christopher D Kassotis; Mathew K Kay; Min Ji Kim; Dominique Lagadic-Gossmann; Sophie Langouet; Antoine Legrand; Zhuorui Li; Helene Le Mentec; Lars Lind; P Monica Lind; Robert H Lustig; Corinne Martin-Chouly; Vesna Munic Kos; Normand Podechard; Troy A Roepke; Robert M Sargis; Anne Starling; Craig R Tomlinson; Charbel Touma; Jan Vondracek; Frederick Vom Saal; Bruce Blumberg Journal: Biochem Pharmacol Date: 2022-04-05 Impact factor: 6.100
Authors: Megan E Romano; Lisa G Gallagher; Melissa N Eliot; Antonia M Calafat; Aimin Chen; Kimberly Yolton; Bruce Lanphear; Joseph M Braun Journal: Int J Hyg Environ Health Date: 2020-11-09 Impact factor: 5.840
Authors: Maryam Zare Jeddi; Teresa Dalla Zuanna; Giulia Barbieri; Aline S C Fabricio; Francesca Daprà; Tony Fletcher; Francesca Russo; Gisella Pitter; Cristina Canova Journal: Int J Environ Res Public Health Date: 2021-01-29 Impact factor: 3.390
Authors: Susanna D Mitro; Sharon K Sagiv; Abby F Fleisch; Lindsay M Jaacks; Paige L Williams; Sheryl L Rifas-Shiman; Antonia M Calafat; Marie-France Hivert; Emily Oken; Tamarra M James-Todd Journal: J Clin Endocrinol Metab Date: 2020-09-01 Impact factor: 5.958
Authors: Elsi Haverinen; Mariana F Fernandez; Vicente Mustieles; Hanna Tolonen Journal: Int J Environ Res Public Health Date: 2021-12-10 Impact factor: 3.390
Authors: Elsi Haverinen; Laura Paalanen; Luigi Palmieri; Alicia Padron-Monedero; Isabel Noguer-Zambrano; Rodrigo Sarmiento Suárez; Hanna Tolonen Journal: Arch Public Health Date: 2021-12-23